Biotech Acquisition (OTCMKTS:BIOTU – Get Free Report) fell 7.7% on Friday . The company traded as low as $10.14 and last traded at $10.14. 1,300 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 4,444 shares. The stock had previously closed at $10.98.
Biotech Acquisition Price Performance
The firm has a 50-day moving average of $10.14 and a 200-day moving average of $10.14.
About Biotech Acquisition
Biotech Acquisition (OTCMKTS: BIOTU) is a special purpose acquisition company organized in Delaware with the purpose of identifying, acquiring, or merging with one or more businesses in the life sciences sector. The company operates as a blank‐check vehicle, raising capital through its initial offering and placing proceeds in a trust until it completes a qualifying business combination. By focusing on biotechnology targets, Biotech Acquisition aims to leverage its structure and funding to support emerging companies in the development, commercialization, and distribution of novel therapeutics and diagnostics.
Since its formation, Biotech Acquisition has sought out opportunities across the United States and internationally, with an emphasis on firms that possess advanced research capabilities in areas such as oncology, gene therapy, and immunology.
Further Reading
- Five stocks we like better than Biotech Acquisition
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
